Dr Hiroyuki MANO National Cancer Center Japan

Biosketch

Dr Hiroyuki Mano is currently the Executive Director and also the Director of Research Institute/Center for Cancer Genomics and Advanced Therapeutics (C-CAT) of National Cancer Center Japan. Dr Mano is also a Member of The Japan Academy.

Back in 2007, Dr Mano published a seminal paper for the discovery of the first, recurrent fusion-type oncokinase, EML4-ALK, in lung adenocarcinoma, and changed the way we think the carcinogenesis of solid tumors. Dr Mano was also the first to identify resistant mutations within EML4-ALK for ALK inhibitors, paving the way to highly effective 2nd/3rdgenerations of ALK inhibitors. He further discovered ROS1-fusion and RET-fusion oncogenes in lung adenocarcinoma. He also revealed the most frequent, yet novel oncogene, DUX4-IGH, in acute lymphoblastic leukemia in adolescents and young adults. Dr Mano recently unveiled that druggable kinase genes are frequently amplified in scirrhous-type (linitis plastica-type) gastric cancer.

As the Director of C-CAT, Dr Mano plays a central role for the cancer genomic medicine under the umbrella of national health insurance system in Japan.

Dr Mano graduated from School of Medicine, The University of Tokyo in 1984, and obtained Ph.D. from the same University in 1992. Dr Mano has been awarded many prestigious prizes such as The Medal of Honor with Purple Ribbon from The Japanese Emperor (2012), The Japan Academy Prize from The Japan Academy (2021) and The Léopold Griffuel Award from Fondation ARC, France (2021).